The treatment goal in IgAN patients at risk of progressive loss of kidney function is to reduce the rate of loss of kidney function to the physiological state (<1 mL/min/year) for the rest of the patient’s life1
Urine protein excretion (UPE) is the only validated early biomarker to help guide clinical decision making, and should be maintained at <0.5 g/day or ideally <0.3 g/day1*
